Effect of bone marrow-derived extracellular matrix on cardiac function after ischemic injury

Biomaterials

Volumn 33, Issue 31, 2012, Pages 7736-7745

  Ravi, Swathi ^a   Caves, Jeffrey M ^b,c,d   Martinez, Adam W ^a   Xiao, Jiantao ^b   Wen, Jing ^b   Haller, Carolyn A ^b,c,d   Davis, Michael E ^a   Chaikof, Elliot L ^a,b,c,d  

^a Emory University   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

Bone marrow; ECM (extracellular matrix); Growth factors; Heart; Porcine tissue; Thermally responsive material

Indexed keywords

ANGIOGENESIS; BENEFICIAL EFFECTS; BONE MARROW; CARDIAC FUNCTIONS; CELL POPULATIONS; ECM (EXTRACELLULAR MATRIX); EXTRACELLULAR MATRICES; FIBROBLAST GROWTH FACTOR-2; FIBROTIC AREA; GROWTH FACTOR; ISCHEMIA-REPERFUSION INJURY; ISCHEMIC HEART DISEASE; ISCHEMIC INJURIES; METHYL-CELLULOSE CARRIER; MYOCARDIAL INFARCTION; PRE-CLINICAL; PROGENITOR CELL; RAT MODEL; THERMALLY RESPONSIVE MATERIAL; TISSUE REPAIR; VASCULAR ENDOTHELIAL GROWTH FACTOR; VENTRICULAR FUNCTIONS;

CELL CULTURE; CELL DEATH; CELL PROLIFERATION; ENDOTHELIAL CELLS; HEART; TISSUE;

BONE;

FIBROBLAST GROWTH FACTOR 2; GLYCOSAMINOGLYCAN; METHYLCELLULOSE; PLATELET DERIVED GROWTH FACTOR BB; SOMATOMEDIN C; STEM CELL FACTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL COUNT; CELL ISOLATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STERNUM; SWINE; TISSUE REPAIR;

ANIMALS; APOPTOSIS; BONE MARROW; BONE MARROW CELLS; CELL ADHESION; CELL PROLIFERATION; EXTRACELLULAR MATRIX; HEART FUNCTION TESTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; METHYLCELLULOSE; MYOCARDIAL ISCHEMIA; RATS; RATS, SPRAGUE-DAWLEY; RHEOLOGY; STEM CELL TRANSPLANTATION; SUS SCROFA;

RATTUS; SUS;

EID: 84865165873     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.07.010     Document Type: Article

References (53)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
2. Tous E., Purcell B., Ifkovits J.L., Burdick J.A. Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res 2011, 4:528-542.
3. Badylak S.F. The extracellular matrix as a biologic scaffold material. Biomaterials 2007, 28:3587-3593.
4. Okada M., Payne T.R., Oshima H., Momoi N., Tobita K., Huard J. Differential efficacy of gels derived from small intestinal submucosa as an injectable biomaterial for myocardial infarct repair. Biomaterials 2010, 31:7678-7683.
5. Singelyn J.M., DeQuach J.A., Seif-Naraghi S.B., Littlefield R.B., Schup-Magoffin P.J., Christman K.L. Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering. Biomaterials 2009, 30:5409-5416.
6. Seif-Naraghi S.B., Salvatore M.A., Schup-Magoffin P.J., Hu D.P., Christman K.L. Design and characterization of an injectable pericardial matrix gel: a potentially autologous scaffold for cardiac tissue engineering. Tissue Eng Part A 2010, 16:2017-2027.
7. Long M.W., Briddell R., Walter A.W., Bruno E., Hoffman R. Human hematopoietic stem cell adherence to cytokines and matrix molecules. J Clin Invest 1992, 90:251-255.
8. Giancotti F.G., Comoglio P.M., Tarone G. Fibronectin-plasma membrane interaction in the adhesion of hemopoietic cells. J Cell Biol 1986, 103:429-437.
9. Koenigsmann M., Griffin J.D., DiCarlo J., Cannistra S.A. Myeloid and erythroid progenitor cells from normal bone marrow adhere to collagen type I. Blood 1992, 79:657-665.
10. Kerst J.M., Sanders J.B., Slaper-Cortenbach I.C., Doorakkers M.C., Hooibrink B., van Oers R.H., et al. Alpha 4 beta 1 and alpha 5 beta 1 are differentially expressed during myelopoiesis and mediate the adherence of human CD34+ cells to fibronectin in an activation-dependent way. Blood 1993, 81:344-351.
11. Quesenberry P., Song Z.X., McGrath E., McNiece I., Shadduck R., Waheed A., et al. Multilineage synergistic activity produced by a murine adherent marrow cell line. Blood 1987, 69:827-835.
12. Bruno E., Luikart S.D., Long M.W., Hoffman R. Marrow-derived heparan sulfate proteoglycan mediates the adhesion of hematopoietic progenitor cells to cytokines. Exp Hematol 1995, 23:1212-1217.
13. Christman K.L., Fok H.H., Sievers R.E., Fang Q., Lee R.J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 2004, 10:403-409.
14. Christman K.L., Vardanian A.J., Fang Q., Sievers R.E., Fok H.H., Lee R.J. Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J Am Coll Cardiol 2004, 44:654-660.
15. Singelyn J.M., Christman K.L. Injectable materials for the treatment of myocardial infarction and heart failure: the promise of decellularized matrices. J Cardiovasc Transl Res 2010, 3:478-486.
16. McAllister T.N., Dusserre N., Maruszewski M., L'Heureux N. Cell-based therapeutics from an economic perspective: primed for a commercial success or a research sinkhole?. Regen Med 2008, 3:925-937.
17. Badylak S.F., Valentin J.E., Ravindra A.K., McCabe G.P., Stewart-Akers A.M. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A 2008, 14:1835-1842.
18. Beattie A.J., Gilbert T.W., Guyot J.P., Yates A.J., Badylak S.F. Chemoattraction of progenitor cells by remodeling extracellular matrix scaffolds. Tissue Eng Part A 2009, 15:1119-1125.
19. Kropp B.P., Rippy M.K., Badylak S.F., Adams M.C., Keating M.A., Rink R.C., et al. Regenerative urinary bladder augmentation using small intestinal submucosa: urodynamic and histopathologic assessment in long-term canine bladder augmentations. J Urol 1996, 155:2098-2104.
20. Kochupura P.V., Azeloglu E.U., Kelly D.J., Doronin S.V., Badylak S.F., Krukenkamp I.B., et al. Tissue-engineered myocardial patch derived from extracellular matrix provides regional mechanical function. Circulation 2005, 112:I144-I149.
21. Valentin J.E., Turner N.J., Gilbert T.W., Badylak S.F. Functional skeletal muscle formation with a biologic scaffold. Biomaterials 2010, 31:7475-7484.
22. Zhao Z.Q., Puskas J.D., Xu D., Wang N.P., Mosunjac M., Guyton R.A., et al. Improvement in cardiac function with small intestine extracellular matrix is associated with recruitment of C-kit cells, myofibroblasts, and macrophages after myocardial infarction. J Am Coll Cardiol 2010, 55:1250-1261.
23. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000, 102:898-901.
24. Rosenblatt-Velin N., Lepore M.G., Cartoni C., Beermann F., Pedrazzini T. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest 2005, 115:1724-1733.
25. Virag J.A., Rolle M.L., Reece J., Hardouin S., Feigl E.O., Murry C.E. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am J Pathol 2007, 171:1431-1440.
26. Iwakura A., Fujita M., Kataoka K., Tambara K., Sakakibara Y., Komeda M., et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 2003, 18:93-99.
27. Wang H., Zhang X., Li Y., Ma Y., Zhang Y., Liu Z., et al. Improved myocardial performance in infarcted rat heart by co-injection of basic fibroblast growth factor with temperature-responsive chitosan hydrogel. J Heart Lung Transplant 2010, 29:881-887.
28. Fujita M., Ishihara M., Morimoto Y., Simizu M., Saito Y., Yura H., et al. Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 in a rabbit model of chronic myocardial infarction. J Surg Res 2005, 126:27-33.
29. Garbern J.C., Minami E., Stayton P.S., Murry C.E. Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 2011, 32:2407-2416.
30. Hsieh P.C., Davis M.E., Gannon J., MacGillivray C., Lee R.T. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest 2006, 116:237-248.
31. Edelberg J.M., Lee S.H., Kaur M., Tang L., Feirt N.M., McCabe S., et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002, 105:608-613.
32. Xaymardan M., Tang L., Zagreda L., Pallante B., Zheng J., Chazen J.L., et al. Platelet-derived growth factor-AB promotes the generation of adult bone marrow-derived cardiac myocytes. Circ Res 2004, 94:E39-E45.
33. Hao X., Silva E.A., Mansson-Broberg A., Grinnemo K.H., Siddiqui A.J., Dellgren G., et al. Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 2007, 75:178-185.
34. Davis M.E., Hsieh P.C., Takahashi T., Song Q., Zhang S., Kamm R.D., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006, 103:8155-8160.
35. Shao Z.Q., Takaji K., Katayama Y., Kunitomo R., Sakaguchi H., Lai Z.F., et al. Effects of intramyocardial administration of slow-release basic fibroblast growth factor on angiogenesis and ventricular remodeling in a rat infarct model. Circ J 2006, 70:471-477.
36. Lopez J.J., Laham R.J., Stamler A., Pearlman J.D., Bunting S., Kaplan A., et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998, 40:272-281.
37. Asahara T., Bauters C., Zheng L.P., Takeshita S., Bunting S., Ferrara N., et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995, 92:II365-II371.
38. Pepper M.S., Vassalli J.D., Orci L., Montesano R. Biphasic effect of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 1993, 204:356-363.
39. Gajdusek C.M., Luo Z., Mayberg M.R. Basic fibroblast growth factor and transforming growth factor beta-1: synergistic mediators of angiogenesis in vitro. J Cell Physiol 1993, 157:133-144.
40. Brogi E., Wu T., Namiki A., Isner J.M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90:649-652.
41. Lynch S.E., Nixon J.C., Colvin R.B., Antoniades H.N. Role of platelet-derived growth factor in wound healing: synergistic effects with other growth factors. Proc Natl Acad Sci U S A 1987, 84:7696-7700.
42. Lynch S.E., Colvin R.B., Antoniades H.N. Growth factors in wound healing. Single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest 1989, 84:640-646.
43. Tate M.C., Shear D.A., Hoffman S.W., Stein D.G., LaPlaca M.C. Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury. Biomaterials 2001, 22:1113-1123.
44. Wells M.R., Kraus K., Batter D.K., Blunt D.G., Weremowitz J., Lynch S.E., et al. Gel matrix vehicles for growth factor application in nerve gap injuries repaired with tubes: a comparison of biomatrix, collagen, and methylcellulose. Exp Neurol 1997, 146:395-402.
45. Wall S.T., Walker J.C., Healy K.E., Ratcliffe M.B., Guccione J.M. Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 2006, 114:2627-2635.
46. Rane A.A., Christman K.L. Biomaterials for the treatment of myocardial infarction: a 5-year update. J Am Coll Cardiol 2011, 58:2615-2629.
47. Rane A.A., Chuang J.S., Shah A., Hu D.P., Dalton N.D., Gu Y., et al. Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction. PLoS One 2011, 6:e21571.
48. van Amerongen M.J., Harmsen M.C., van Rooijen N., Petersen A.H., van Luyn M.J. Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. Am J Pathol 2007, 170:818-829.
49. Leor J., Rozen L., Zuloff-Shani A., Feinberg M.S., Amsalem Y., Barbash I.M., et al. Ex vivo activated human macrophages improve healing, remodeling, and function of the infarcted heart. Circulation 2006, 114:I94-100.
50. Nakajima T., Hishikari K., Ogawa M., Watanabe R., Suzuki J., Nagashima A., et al. Clarithromycin attenuates myocardial ischemia-reperfusion injury. Expert Opin Ther Targets 2010, 14:881-893.
51. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
52. Fazel S., Cimini M., Chen L., Li S., Angoulvant D., Fedak P., et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006, 116:1865-1877.
53. Rota M., Kajstura J., Hosoda T., Bearzi C., Vitale S., Esposito G., et al. Bone marrow cells adopt the cardiomyogenic fate in vivo. Proc Natl Acad Sci U S A 2007, 104:17783-17788.